Tag: setrusumab

September 5, 2019 Off

Mereo to present its osteogenesis imperfecta study data in Orlando

By Dino Mustafić

Mereo BioPharma will present the 6-month interim data from the open label arm of the its Phase 2b dose-ranging clinical study of setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta (OI) at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL.